Make a Donation

Scope

The LHCE carries out investigations at the interface of basic and clinical cancer research.

Our investigations focus on the molecular mechanisms that govern cell death and the cellular resistance to chemotherapy in hematological and non-hematological cancers. We carry out fundamental research projects and are also actively involved in the identification of promising therapeutic strategies, including novel combination strategies for extending patient survival. Important cell death pathways that are the focus of current studies include apoptosis and autophagy. Other lines of research also explore the mechanisms underlying the repair of DNA damage induced by anticancer drugs, and the role of DNA repair proteins in genomic stability and chromatin integrity. Recently, studies aiming to discover cancer protein and miRNA biomarkers in blood samples have been initiated and implemented in the laboratory in order to improve early diagnostic and treatment. 

Contact

Laboratory of Experimental Hemato-Oncology
Head of Research Unit: Dr. Guy Berchem
CRP-Santé, BAM
84, Val Fleuri, L-1526 Luxembourg
Tel: (+352) 44 11 20 84
Secretary: audrey.lemasson@crp-sante.lu
Phone: (+352) 26 970 320
Fax: (+352) 44 12 15
E-mail: berchem.guy@chl.lu

Find on Google Map

Make a Donation

MOLECULAR MECHANISMS THAT GOVERN CELL DEATH AND THE CELLULAR RESISTANCE TO CHEMOTHERAPY IN HEMATOLOGICAL AND NON-HEMATOLOGICAL CANCERS

‹ Back

Overview

Chemoterapy is one the cornerstones of cancer management. Unfortunately, chemoresistance mechanisms often occur that contribute to disease progression and mortality. Understanding how these mechanisms operate and developing new therapeutic targets as well as new combination regimens therefore represents a challenge of considerable importance. In the laboratory, several lines of research are developed to understand the molecular details of the cell death pathways that underlie the response to anti-cancer drugs.